Personalised medicine to drive global lung cancer market to 2020
pharmafile | November 29, 2016 | News story | Manufacturing and Production, Sales and Marketing | Technavio, lung cancer, non-small cell lung cancer
According to a new report from Technavio, the global lung cancer therapeutics market is projected to grow at more than a 9% compound annual growth rate until 2020. Targeted therapy within the market sector and a growing prevalence of the disease is cited as a major drive for this growth.
Top-selling targeted therapies including Tarceva, Avastin and Cyramza draw 40% of their annual sales from the US market alone; thus, the report notes that the Americas in particular will be a prime driver and beneficiary of this growth. While the majority of patients in Brazil (46%) are treated with chemoradiotherapy as the standard of care to tackle non-small cell lung cancer (NSCLC), the region has been moving toward greater adoption of targeted therapies. By contrast 81% of US patients use Tarceva as a first-line EGFR mutant therapy for NSCLC.
These trends continue across the pond in EMEA, where a rising incidence of lung cancer is likely to drive growth in the sector, just as it is expected to in the US and beyond. With lung cancer as the leading cancer-related cause of death in Europe, the race for developments in effective personalised medicine is expected to push investment in the sector.
The report also notes that, in part because of the growing number of smokers in Asia, 51% of all lung cancer cases worldwide occur within the region, which has led pharma players to target emerging economies, though the lower average income in these regions is expected to prove problematic in making high-cost drugs available effectively.
“The global lung cancer therapeutics market is expected to benefit from the growing incidence of lung cancer worldwide,” Sapna Jha, a lead oncology research expert from Technavio, explained. “According to National Cancer Institute, in 2012, there were approximately 1.8 million new cases of lung cancer. The increasing adoption of targeted therapies, particularly in developed countries, is expected to drive market growth.”
The report further highlights the sector’s top firms in the next four years to include Eli Lilly, AstraZeneca, Pfizer and Celgene.
Matt Fellows
Related Content
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy …
